课题基金 / 基金详情

Rapid Microfluidic-Based Point-of-Care Assessment of Epigenetic Marks for Diagnosis, Prognosis and Response to Therapy in Critical Illness

Rapid Microfluidic-Based Point-of-Care Assessment of Epigenetic Marks for Diagnosis, Prognosis and Response to Therapy in Critical Illness
基于微流控的快速护理点表观遗传标记评估,用于危重疾病的诊断、预后和治疗反应
批准号:
549575-2020
负责人:
DosSantos, ClaudiaChimisso
金额:
$20.51万
依托单位:
依托单位国家:
加拿大
项目类别:
Collaborative Health Research Projects
财政年份:
2020
资助国家:
加拿大
项目状态:
已结题
起止时间:
2020-01-01 至 2021-12-31

项目摘要

项目成果

DosSantos, ClaudiaChimisso的其他基金

相似基金

相关文献

中文摘要
翻译
败血症,全身炎症和器官衰竭都是由压倒性的
英文摘要
Sepsis, whole body inflammation and organ failure triggered by an overwhelming and unbalanced response to infection, incurs enormous human and health care costs. Globally, over 30 million people are affected each year, at least a quarter of whom will die. The sequelae include physical, mental, and psychological disability. Currently, no specific treatments exist. For cancer patients, personalizing treatment on the basis of molecular characteristics of a tumor is simply good practice. There is an urgent need to do the same for sepsis. We have identified tags on DNA (DNA methylation marks) that can classify septic vs. non-septic patients, the likelihood of poor outcomes (death and organ failure) and response to therapy (blood pressure medications). In parallel, our partners have developed and patented a point-of-care device that uses an innovative microfluidic approach to isolate DNA from whole blood. We propose to adapt this technology to develop a prototype able to perform automated measurements of DNA marks from patients using whole blood; to test our device on banked DNA and whole blood samples; to use predictive modeling to integrate clinical and molecular data to validate outcome prediction and response to therapy in an independent cohort; and to test the performance of our prototype and precision marks prospectively in a real-world situation. Both the technology and biomarker detection approaches have never been tried for sepsis before. This proposal brings together bioengineers, health research scientists, bioinformaticians, physicians and clinical biochemists. Successful completion will provide a Lab-on-chip technology employing low-cost industrially manufacturable polymer microfluidic devices powered by an advanced patented centrifugal microfluidic technology that promises to be a disruptive innovation in the way to integrate and deploy genomic knowledge practical devices that will impact clinical practices and the care of the critically ill.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rapid Microfluidic-Based Point-of-Care Assessment of Epigenetic Marks for Diagnosis, Prognosis and Response to Therapy in Critical Illness
  • 批准号:
    549575-2020
  • 项目类别:
    Collaborative Health Research Projects
  • 资助金额:
    $9.77万
  • 财政年份:
    2021
  • 负责人:
    DosSantos, ClaudiaChimisso
  • 依托单位:
国内基金
海外基金
基于RPA-microfluidic chip技术高效诊断侵袭性真菌病的研究
  • 批准号:
    2020A151501763
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2020
  • 负责人:
    马庆林
  • 依托单位:
利用Microfluidic系统研究血流速度对巨核细胞生成血小板的信号调控机制
  • 批准号:
    81770131
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2017
  • 负责人:
    戴菁
  • 依托单位: